Tampa, Fla. (PRWEB) September 02, 2014 Scientists, physicians, patients, families, and community leaders will join together in Tampa Bay from September 4-6 for the Friedreichs Ataxia Research Alliances (FARA) sixth annual Scientific Symposium and FARA Energy Ball Gala. The Energy Ball benefits FARA and the USF Ataxia Research Center in their pursuit of treatment and cure for the 15,000 people worldwide affected by the progressive neuromuscular disease Friedreichs ataxia (FA). The annual gathering provides an excellent chance for scientists to discuss research developments, for patients and their families to be updated on advancements, and for those who care about FA to lend a supportive hand, says Ronald Bartek, President of FARA. FA is the most common of the inherited ataxias. Over the course of the disease, individuals develop balance issues often leading to full-time wheelchair use, impaired speech, hearing and vision loss, and ultimately, a shortened lifespan due to heart complications. Currently, there is no known treatment or cure for FA. International leaders in FA research and the FA community will attend the Understanding Energy for a Cure Scientific Symposium on September 4 to discuss advancements in FA therapeutic approaches. Updates of ongoing drug discovery efforts, clinical trials, along with … Continue reading →

PUBLIC RELEASE DATE: 3-Sep-2014 Contact: Ron Gilmore rlgilmore1@mdanderson.org 713-745-1898 University of Texas M. D. Anderson Cancer Center Parents of twins often tell them apart through subtle differences such as facial expression, moles, voice tone and gait. Similarly, physicians treating women with endometrial cancer must be able to distinguish between different versions of this disease form that, on the surface, appear the same. With endometrial cancer, the most common gynecological cancer in the western world and the fourth most prevalent in the U.S., it can literally be a matter of life and death. Mortality rates from this cancer have nearly tripled in the last 25 years and are thought to be attributed to the rising incidence of obesity. Scientists at The University of Texas MD Anderson Cancer Center in Houston have identified genetic mutations in endometrioid endometrial carcinoma (EEC), the most common form of this cancer of the uterine lining. The mutations revealed a more lethal version of an EEC subtype previously thought to respond well to treatment. It's possible that by identifying these patients early on, oncologists can try more aggressive treatment approaches to increase the likelihood for a positive outcome. "EEC is categorized into subtypes that help determine risk … Continue reading →

ReNeuron Group Quote more Price: 3.62 Chg: -0.19 Chg %: -4.87% Date: 16:38 Stem cell therapy group Reneuron said it remains on track with the first patients having been dosed in two its clinical trials. The phase II trial for the ReN001 cell therapy candidate for stroke disability and the phase I trail for ReN009 cell therapy candidate for critical limb ischaemia have both begun. The ReN001 trial is on course to have generated six month follow-up data by the end of 2015, while ReN009 study should give results in the first half of next year. Chief executive officer (CEO) Michael Hunt said that Reneuron's core therapeutic programmes remain on track towards "further important clinical milestones" over the next 18 months. "In particular, the commencement of dosing of patients in two new clinical trials, in stroke and limb ischaemia, marks another significant step in Reneuron's evolution into a fully-fledged clinical development business and a leading player in the increasingly exciting field of cell therapy and regenerative medicine," Hunt said. View post: Reneuron on track for clinical milestones as studies get underway … Continue reading →

Richfeel: Have a great hair day Dr. Apoorva Shah Dr. Sonal Shah, India's leading trichologists and founder of Richfeel Hair and Scalp Clinic, talk about Hair fall Hair prevention. Also, explaining about plant stem-cell... By: Richfeel Trichology … Continue reading →